Essential blepharospasm

被引:0
作者
Wabbels, B. [1 ]
Roggenkaemper, P. [1 ]
机构
[1] Univ Augenklin Bonn, D-53127 Bonn, Germany
来源
OPHTHALMOLOGE | 2012年 / 109卷 / 01期
关键词
Essential blepharospasm; Botulinum toxin; Xeomin; Duration of effect; Injection interval; TOXIN TYPE-A; INDUCED THERAPY FAILURE; QUALITY-OF-LIFE; BOTULINUM-TOXIN; CERVICAL DYSTONIA; HEMIFACIAL SPASM; ANTIBODY; IMMUNOGENICITY; PREVALENCE; INJECTIONS;
D O I
10.1007/s00347-011-2457-z
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Botulinum neurotoxin injections are a primary symptomatic treatment for blepharospasm. Injections are generally repeated every 3 months. For patients with short-term treatment effects there have therefore been long intervals without sufficient treatment effects, as reinjections have previously been avoided due to concerns of increased side effects or production of antibodies against complexing proteins. As XeominA (R) is a pure A botulinum toxin type complexing proteins are not present. We have hence decided to treat appropriate patients with injection intervals of 10 or less weeks if these patients have been suffering from psychological stress. In 11 of these patients the typical patient characteristics and course of therapy were analyzed. There were no relevant adverse events. In all patients, time periods without treatment effect were shorter or no longer present. In 6 patients injection intervals could be prolonged after several injections due to the good effect. An optimized therapy of essential blepharospasm should not only take dose, dose distribution and injections site into account but also injection intervals. Reinjections could be performed if necessary after at least 6 weeks.
引用
收藏
页码:45 / +
页数:8
相关论文
共 33 条
[1]   Basic immunological aspects of botulinum toxin therapy [J].
Atassi, MZ .
MOVEMENT DISORDERS, 2004, 19 :S68-S84
[2]   Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs [J].
Bentivoglio, A. R. ;
Fasano, A. ;
Ialongo, T. ;
Soleti, F. ;
Lo Fermo, S. ;
Albanese, A. .
NEUROTOXICITY RESEARCH, 2009, 15 (03) :224-231
[4]   Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay [J].
Brin, Mitchell F. ;
Comella, Cynthia L. ;
Jankovic, Joseph ;
Lai, Francis ;
Naumann, Markus .
MOVEMENT DISORDERS, 2008, 23 (10) :1353-1360
[5]  
Ceballos-Baumann AO, 1996, BEWEGUNGSSTORUNGEN N
[6]  
Chinnapongse R, 2010, NEUROLOGY, V74, P86
[7]   Botulinum toxin type B de novo therapy of cervical dystonia - Frequency of antibody induced therapy failure [J].
Dressler, D ;
Bigalke, H .
JOURNAL OF NEUROLOGY, 2005, 252 (08) :904-907
[8]   Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy [J].
Dressler, D .
EUROPEAN NEUROLOGY, 2002, 48 (01) :26-29
[9]   Complete secondary botulinum toxin therapy failure in blepharospasm [J].
Dressler, D .
JOURNAL OF NEUROLOGY, 2000, 247 (10) :809-810
[10]   New formulation of BOTOX® -: Complete antibody-induced therapy failure in hemifacial spasm [J].
Dressler, D .
JOURNAL OF NEUROLOGY, 2004, 251 (03) :360-360